Participated · Seed · Feb 2026

Founded in 2021 and based in Budapest, Allonic is a robotics hardware company pioneering a proprietary 3D Tissue Braiding process that weaves soft-tissue-like fibres around skeletal cores to create fully integrated robotic limbs and bodies in a single automated step. By replacing assembly-heavy designs with continuous fabrication, the platform removes supply-chain complexity and cuts iteration cycles from weeks to minutes, allowing users to design, build and replace manipulators on demand. The system can embed multiple materials—including elastics, wiring and sensors—directly into the structure, producing safer, more compliant and customisable robots at lower cost. Allonic has already completed its first pilot in electronics manufacturing after unveiling the technology in May 2025, demonstrating applicability where traditional industrial robots fall short. The company plans to use new capital to accelerate platform development, grow its engineering and operations teams, and run further pilots and early commercial deployments with industrial partners. Its €6 million pre-Seed round is the largest such financing recorded in Hungary to date, underscoring investor conviction in its infrastructure-level approach to robotics. While no revenue figures have been disclosed, the early traction positions Allonic to address a growing gap between advanced AI control software and legacy hardware manufacturing.

Participated · Seed · Jan 2022

Rhaeos is a clinical-stage medical device company focused on addressing unmet needs in the care of people with hydrocephalus and developing wearable sensors for chronic conditions. Its core product, the FlowSense shunt monitor, is a wireless, non-invasive thermal sensor delivered as a small, bandage-sized patch that adheres above implanted shunt tubing. FlowSense rapidly monitors shunt function and wirelessly transmits critical data to a mobile app in minutes to support clinical decision making. Rhaeos received FDA Breakthrough Device Designation for FlowSense in 2020 and is currently evaluating the device in a multi-center FDA pivotal study in the US. The company intends to use the Series A proceeds to support an in-hospital launch of FlowSense and anticipates making the monitor commercially available to physicians and patients in 2023. The company is led by CEO Anna Lisa Somera. Rhaeos is a private, clinical-stage medical device company based in Evanston, Ill., formed out of the John A. Rogers Research Group at Northwestern University. The company is developing FlowSense™, a noninvasive wireless wearable sensor that addresses a clinical unmet need for patients with hydrocephalus and is initially targeted at the neurosurgical suite. Rhaeos has received support from federal and nonprofit sources, including the National Institutes of Health and the National Science Foundation, as well as foundations and pediatric device consortia. The company closed a $2.2M seed financing and has secured more than $8M in total dilutive and non-dilutive financing to date. Proceeds from the seed round will be used to prepare for the 2022 commercial launch of FlowSense. Additional institutional and accelerator supporters include MedTech Innovator and several pediatric device accelerators and consortiums.

Participated · Seed · Jun 2021

asensei, founded in 2014 by CEO Steven Webster and based in San Francisco, builds a Connected Coaching technology platform that delivers technique coaching and correction for sport and fitness products. Its offerings include motion-capture-enabled apparel, SDK coaching kits to connect apparel to apps and equipment, a technique library of exercises and faults, and blueprint UX/code templates to speed integration. The platform is designed for apparel and equipment providers, connected fitness companies, and brick-and-mortar facilities to strengthen engagement, lock in loyalty, and improve retention by turning solo practice into instructional learning. The team is training the system to coach hundreds of exercises across activities including rowing, yoga, pilates, rehabilitation, kettlebells and TRX, while delivering roadmap blueprint solutions to accelerate partners' time to market. The company closed a $2.2M seed round and has total funding of $5.1M. asensei intends to use the proceeds to accelerate growth as a B2B provider to fitness and physical therapy brands.

Participated · Series B · Jan 2021

Ocient builds data analytics software that delivers high-performance, compute-intensive analysis of very large and complex datasets using technologies such as Compute Adjacent Storage Architecture (CASA), Megalane™, OcientML®, and OcientGeo®. The company offers pilot-to-production deployments on premises, in the OcientCloud®, or in public clouds and emphasizes up to 90% price savings and reduced environmental impact. Ocient plans to use new capital to advance development and delivery of energy-efficient solutions for costly, complex, and operationally burdensome data and AI workloads and to expand customer deployments globally. The startup reported doubling revenues for the third straight year as it transitions into growth stage and has deepening industry partnerships with AMD, Solidigm, Amdocs, and others. Ocient was also accepted into the NVIDIA Inception program and recently launched a named telecommunications solution for data retention and disclosure. The company appointed Henry Marshall as CFO to manage financial operations as it scales. Ocient provides data analytics software that enables always-on, compute-intensive analysis of large, complex datasets, including in-database ML and geospatial capabilities. Its Compute Adjacent Storage Architecture (CASA) removes network bottlenecks to facilitate rapid data access and supports always-on loading, ETL/ELT, Zero Copy Reliability™, OcientML™, and OcientGeo™. The company says its platform delivers energy and cost efficiencies—including up to 80% price savings—and is positioned for next-generation, growth-scale analytics. Enterprises can deploy Ocient on premises, in OcientCloud™, or in the public cloud with minimal integration from pilot to production. Ocient reported 109% year-over-year revenue growth in its last fiscal year and plans to use new funding to advance product capabilities and deliver hyperscale data analytics solutions to a growing global customer base. Founded in 2016, Ocient is a global, carbon-neutral company headquartered in Chicago and has been recognized in the GigaOm Radar for Data Warehouses as a Fast Mover and Challenger. Ocient provides a proprietary data analytics solution (Ocient DAS) designed to enable rapid analysis of extremely large datasets. The platform can hold quadrillions of rows, ingest billions of rows per second, and filter and compute across trillions of rows per second. Ocient is deploying its DAS in Auction & Exchange Analytics, Security, and Geospatial customer use cases using industry-standard interfaces and hardware. The company was co‑founded in March 2016 by Chris Gladwin, Joseph Jablonski, and George Kondiles. Ocient closed a $40M Series B that brought total invested capital to $65M. The company plans to use the funds to grow engineering, customer success, operations, and sales and marketing, and expects headcount to double to 150 by the end of 2021. Ocient builds an ultra-large-scale relational database platform and SaaS designed to analyze multi-petabyte to exabyte-class datasets with interactive, sub-second query latency. Its DAS product can hold quadrillions of rows, ingest billions of rows per second, and filter/compute trillions of rows per second, and runs on commodity hardware or public cloud. The system targets use cases where NoSQL and Hadoop fall short, offering massively parallel processing and benchmarks that are typically ~50× faster than alternatives such as Presto (and up to 1,000× in some comparisons). The company says analytics that once took an hour can now take 10 seconds or less, enabling interactive insights on previously intractable datasets. Ocient has been expanding its team (hiring 15 employees and 9 interns in 2020 to reach over 50 employees) and plans to more than double headcount over the following year. The company also added senior management and advisory board members as it scales commercial and technical efforts. Ocient builds a relational database and analytics software platform designed to handle petabyte- to exabyte-scale data sets. Its platform is engineered to hold quadrillions of rows, ingest data at speeds of billions of rows per second, and filter and compute results at rates up to trillions of rows per second. The product targets organizations that need to analyze immense amounts of data at extreme scale. The company will use the new capital to support its engineering team, continue research and development, and activate a new development lab. Ocient was co-founded by Chris Gladwin, Joseph Jablonski and George Kondiles and is based in Chicago, IL. It secured about $10M in Series A funding to advance product and engineering work.

Participated · Series B · Dec 2017

Aptinyx is an Evanston, IL–based clinical-stage biopharmaceutical company developing novel, small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors. Its chemistry and discovery platform has generated clinical drug candidates NYX-2925 and NYX-783, which have demonstrated high oral bioavailability, diverse NMDA receptor subtype binding profiles, differentiated preclinical efficacy, and favorable safety. NYX-2925 is in a Phase 2 study for neuropathic pain associated with diabetic peripheral neuropathy and an exploratory study in fibromyalgia; the FDA granted Fast Track designation for NYX-2925 in DPN. NYX-783 has initiated a Phase 1 study to evaluate safety and tolerability and is being developed for PTSD, for which the FDA has also granted Fast Track designation. The company completed a $70M Series B and intends to use the funds to advance its clinical-stage pipeline, support clinical studies of NYX-2925 and NYX-783, advance a third proprietary compound into the clinic in 2018, initiate development in new indications, and continue discovery of additional NMDA receptor modulators. Led by CEO Norbert Riedel, Aptinyx plans to progress multiple clinical and discovery-stage programs using the new financing. Aptinyx develops novel small‑molecule modulators of the N‑methyl‑D‑aspartate (NMDA) receptor aimed at treating difficult neurological disorders. The company operates a proprietary chemistry platform for discovering orally bioavailable NMDA receptor modulators that enhance synaptic plasticity. Aptinyx has completed IND‑enabling studies for its first clinical candidate and plans to initiate Phase 1 studies in mid‑2016. The $65M Series A financing will be used to conduct initial clinical studies of the lead drug candidate and to discover additional small‑molecule modulators. The company is led by president and CEO Norbert Riedel, Ph.D., and is based in Evanston, Illinois.